The latest price target for Mira Pharmaceuticals (NASDAQ:MIRA) was reported by Rodman & Renshaw on September 30, 2024. The analyst firm set a price target for $17.00 expecting MIRA to rise to within 12 months (a possible 1228.13% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Mira Pharmaceuticals (NASDAQ:MIRA) was provided by Rodman & Renshaw, and Mira Pharmaceuticals initiated their buy rating.

There is no last upgrade for Mira Pharmaceuticals

There is no last downgrade for Mira Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mira Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mira Pharmaceuticals was filed on September 30, 2024 so you should expect the next rating to be made available sometime around September 30, 2025.

While ratings are subjective and will change, the latest Mira Pharmaceuticals (MIRA) rating was a initiated with a price target of $0.00 to $17.00. The current price Mira Pharmaceuticals (MIRA) is trading at is $1.28, which is within the analyst’s predicted range.